DNMTI

This program centers on the in vitro and in vivo validation of a new series of inhibitors of DNA Methyl Transferase (DNMT), a target involved in the modulation of gene expression. Drugs which act against DNMT are currently being used in the clinic, and this program will leverage newly acquired inhibitors that could be active on both solid and liquid tumors, as well as having improved pharmacokinetic and safety profiles. Experiments looking at the compounds’ efficacy in liquid tumor animal models will be conducted. This program is a collaboration between Dr. Daifuku (Seattle, Washington) and Dr. Momparler (Ste Justine, Montreal).